Mylan Laboratories Limited — Rivaroxaban Exporter Profile
Indian Pharmaceutical Exporter · #1 for Rivaroxaban · $12.8M export value · DGFT Verified
Mylan Laboratories Limited is the #1 Indian exporter of Rivaroxaban with $12.8M in export value and 257 verified shipments. Mylan Laboratories Limited holds a 24.4% market share in Rivaroxaban exports across 11 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.
Mylan Laboratories Limited — Rivaroxaban Export Profile: Buyers & Destinations
Where Does Mylan Laboratories Limited Export Rivaroxaban?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $3.3M | 195 | 77.1% |
| FRANCE | $435.2K | 16 | 10.0% |
| ZIMBABWE | $272.8K | 10 | 6.3% |
| THAILAND | $128.3K | 9 | 3.0% |
| BELGIUM | $68.6K | 2 | 1.6% |
| GERMANY | $62.2K | 5 | 1.4% |
| ITALY | $23.8K | 3 | 0.5% |
| SOUTH AFRICA | $3.0K | 1 | 0.1% |
| MALTA | $583 | 9 | 0.0% |
| MEXICO | $199 | 4 | 0.0% |
Mylan Laboratories Limited exports Rivaroxaban to 11 countries. The largest destination is NETHERLANDS accounting for 77.1% of Mylan Laboratories Limited's Rivaroxaban shipments, followed by FRANCE (10.0%) and ZIMBABWE (6.3%). These destinations reflect Mylan Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Rivaroxaban from Mylan Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN IRELAND C/O ALLOGA RDC, | NETHERLANDS | $1.5M | 83 |
| MYLAN IRELAND C/O ALLOGA RDC,. | NETHERLANDS | $617.9K | 46 |
| MYLAN IRELAND | NETHERLANDS | $565.2K | 33 |
| MYLAN IRELAND C/O ALLOGA RDC | NETHERLANDS | $259.2K | 15 |
| CSP VIATRIS SANTE AT CSP- LABO, | FRANCE | $241.1K | 12 |
| CSP | FRANCE | $204.6K | 5 |
| REMED PRIVATE LIMITED | ZIMBABWE | $175.9K | 6 |
| MYLAN IRELAND C O ALLOGA RDC | NETHERLANDS | $138.5K | 7 |
| VIATRIS PHARMACEUTICALS (THAILAND) | THAILAND | $128.3K | 9 |
| BGP PRODUCTS GMBH, | NETHERLANDS | $92.3K | 4 |
Mylan Laboratories Limited supplies Rivaroxaban to 23 buyers globally. The largest buyer is MYLAN IRELAND C/O ALLOGA RDC, (NETHERLANDS), followed by MYLAN IRELAND C/O ALLOGA RDC,. (NETHERLANDS) and MYLAN IRELAND (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Rivaroxaban Export Value and How Much Does Mylan Laboratories Limited Contribute?
India exported $36.7M worth of Rivaroxaban through 5,361 shipments from 221 suppliers to 115 countries, serving 497 buyers globally. Mylan Laboratories Limited contributes $12.8M to this total, accounting for 24.4% of India's Rivaroxaban exports. Mylan Laboratories Limited ships Rivaroxaban to 11 countries through 23 buyers.
What Is the Average Shipment Value for Mylan Laboratories Limited's Rivaroxaban Exports?
Mylan Laboratories Limited's average Rivaroxaban shipment value is $50.0K per consignment, based on 257 shipments totaling $12.8M. The largest destination is NETHERLANDS (77.1% of Mylan Laboratories Limited's Rivaroxaban exports).
How Does Mylan Laboratories Limited Compare to Other Indian Rivaroxaban Exporters?
Mylan Laboratories Limited ranks #1 among 221 Indian Rivaroxaban exporters with a 24.4% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($12.8M), DR.REDDY'S LABORATORIES LTD ($5.2M), ZENTIVA PRIVATE LIMITED ($3.2M). Mylan Laboratories Limited processed 257 shipments to 11 destination countries.
What Rivaroxaban Formulations Does Mylan Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| RIVAROXABAN VIATRIS 20 MG 28BL PACKS 2X14 S BLISTER 274358 PACKS X 2X14 S 7682024 NOS | $100.0K | 2 |
| RIVAROXABAN TAB 20MG 100BT FI/SE VIA PACKS 26233NOS | $83.5K | 3 |
| RIVAROXABAN TAB 20MG 10BL SSA MY 1 X 10S BLISTER | $75.5K | 2 |
| RIVAROXABAN TAB 10MG 30BL FR VIA (PACKS 3 X 10S BLISTER)(73105 PACKS X 3X10S=2193150 NOS)NOS | $55.6K | 3 |
| RIVAROXABAN TAB 10MG 10BL SSA MY 1 X 10S BLISTER | $51.3K | 2 |
| HARMLESS MEDICINES RIVAROXABAN VIATRIS20 MG 28BL TAB 29837 PACKS | $50.0K | 1 |
| HARMLESS MEDICINES RIVAROXABAN VIATRIS20 MG 28BL TAB 39639 PACKS | $50.0K | 1 |
| HARMLESS MEDICINES RIVAROXABANO ANOVA 20 MG 28BL TAB 39585 PACKS | $50.0K | 1 |
| HARMLESS MEDICINES RIVAROXABAN TAB 15MG42BL PT VIA 28605 PACKS | $50.0K | 1 |
| HARMLESS MEDICINES, RIVAROXABAN TAB 10MG30BL IE VIA (2760 PACKS) | $50.0K | 1 |
Mylan Laboratories Limited exports 214 distinct Rivaroxaban formulations including tablets, capsules, syrups, and combination drugs. The top formulation is RIVAROXABAN VIATRIS 20 MG 28BL PACKS 2X14 S BLISTER 274358 P with 2 shipments worth $100.0K.
How Does Mylan Laboratories Limited Compare to Nearest Rivaroxaban Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED ★ | $12.8M | 257 | 11 | $50.0K |
| 2 | DR.REDDY'S LABORATORIES LTD | $5.2M | 131 | 12 | $39.6K |
| 3 | ZENTIVA PRIVATE LIMITED | $3.2M | 148 | 2 | $21.5K |
Mylan Laboratories Limited ranks #1 among 221 Indian Rivaroxaban exporters. Average shipment value of $50.0K compared to the market average of $166.0K. The closest competitors by value are DR.REDDY'S LABORATORIES LTD and ZENTIVA PRIVATE LIMITED.
Which Indian Ports Ship Rivaroxaban Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,144 | 21.3% |
| DELHI AIR CARGO ACC (INDEL4) | 985 | 18.4% |
| DELHI AIR | 659 | 12.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 635 | 11.8% |
| Bombay Air | 197 | 3.7% |
| NHAVA SHEVA SEA (INNSA1) | 164 | 3.1% |
| Delhi Air | 133 | 2.5% |
| HYDERABAD AIR | 110 | 2.1% |
What Other Cardiovascular Products Does Mylan Laboratories Limited Export?
Mylan Laboratories Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Rivaroxaban Exports
Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.
In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.
Mylan Laboratories Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.
The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.
About Mylan Laboratories Limited
Mylan Laboratories Limited exports 91 products worth $634.8M. Beyond Rivaroxaban, top products include Tenofovir, Pantoprazole, Valsartan, Ritonavir, Trastuzumab. View the complete Mylan Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Rivaroxaban — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Rivaroxaban shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 257 individual customs records matching Mylan Laboratories Limited exporting Rivaroxaban, covering 214 formulations to 11 countries via 23 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 115+ countries, 497+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Rivaroxaban Export Data from Mylan Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Mylan Laboratories Limited's Rivaroxaban exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Mylan Laboratories Limited
Full Company Profile →
91 products · $634.8M total trade · 26 categories
Rivaroxaban Stats
Company Overview
Top Products by Mylan Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Mylan Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rivaroxaban. For current shipment-level data, contact TransData Nexus.